Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Seattle Genetics seals two drug pacts
January 15, 2007
| A version of this story appeared in
Volume 85, Issue 3
Seattle Genetics has secured two antibody drug development deals. Genentech paid $60 million up front for exclusive rights to SGN-40, a humanized monoclonal antibody in Phase I and II clinical trials to treat a range of cancers. Seattle Genetics could earn up to $800 million in milestone payments, as well as royalties of more than 10% on sales of the drug. Genentech will cover all costs for development of the drug. Separately, Seattle Genetics will collaborate with Agensys to develop antibody-drug conjugates to treat cancer. The ADCs will combine Agensys antibodies with Seattle Genetics' conjugation technology.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter